Jaguar Health Announces Initial OnTarget Study Results; Multicenter, Double-Blind, Placebo-Controlled Pivotal Clinical Trial Did Not Meet Primary Endpoint
Portfolio Pulse from Benzinga Newsdesk
Jaguar Health announced that its OnTarget study, a multicenter, double-blind, placebo-controlled pivotal clinical trial, did not meet its primary endpoint.
July 23, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Jaguar Health's OnTarget study, a pivotal clinical trial, failed to meet its primary endpoint. This could negatively impact investor sentiment and the stock price in the short term.
The failure to meet the primary endpoint in a pivotal clinical trial is a significant setback for any biotech company. Investors often react negatively to such news, leading to a potential decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100